TRANSCENTA-B (06628) partner Inhibrx announces positive results from Phase II clinical trials of ozekibart for the treatment of chondrosarcoma, with plans to submit a BLA in 2026 for performance progress.

TRANSCENTA-B(06628) announced that its partner, Inhibrx Biosciences, Inc. (Inhibrx, NASDAQ code: INBX), has released positive top-line results from the registrational clinical study ChonDRAgon (n=206). The study evaluated the efficacy of ozekibart (INBRX-109) as monotherapy compared to placebo in patients with advanced or metastatic, unresectable chondrosarcoma. Based on these results, Inhibrx plans to submit a marketing authorization application for ozekibart for chondrosarcoma indication in the United States by the end of June 2026. As per the licensing agreement signed through its wholly-owned subsidiary Hangzhou Yianjishi Biopharmaceutical Co., Ltd. (HJB), the company has exclusive development and commercialization rights to ozekibart (INBRX-109) in mainland China, Hong Kong Special Administrative Region of China, Macau Special Administrative Region of China, and Taiwan. Ozekibart is the first investigational drug to significantly improve progression-free survival in chondrosarcoma patients in a randomized controlled trial, with no approved systemic treatment for the disease currently available. The encouraging clinical data further confirm the value of the product for patients worldwide and in the company's exclusive licensed regions. In addition to the registrational clinical trial, Inhibrx is also advancing the expansion cohorts of ozekibart, evaluating its combination with irinotecan-based regimens for the treatment of Ewing's sarcoma and colorectal cancer. Early results show promising signals, supporting further exploration of the potential of ozekibart in these unmet medical needs in refractory tumors.